Clinical trials
Metabolic Associated Fatty Liver Disease clinical trials
Below are recruiting metabolic associated fatty liver disease clinical trials, each written for real people, not researchers. We’re tracking 73 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07246421Recruiting
Glucagon resistance in fatty liver and diabetes
This study looks at how people with fatty liver and type 2 diabetes respond to glucagon, a hormone that helps control blood sugar. It may help researchers understand a condition called 'glucagon resistance' and find better treatments.
AarhusAges 30–70 - NCT07270601Recruiting
Ultrasound test for liver fat
This study is testing a new ultrasound method to measure fat in the liver. It is for people who may have a liver condition or have risk factors like diabetes or obesity, as well as healthy volunteers.
Seattle, WashingtonAges 18–75 - NCT07321925Recruiting
Using sound waves to measure liver fat
This study tests a new method that uses sound waves to measure fat in your liver. It could help doctors check liver health without a biopsy.
Ann Arbor, MichiganAges 18 years+ - NCT07481734RecruitingPhase 2
Tesamorelin for reducing liver fat in fatty liver disease
This trial tests if tesamorelin, a daily injection, can reduce liver fat in adults with fatty liver disease. It may help people whose liver has fat but is not yet scarred into cirrhosis.
Shenzhen, GuangdongAges 18–75 - NCT07518784Recruiting
Testing a new liver scanning device for fatty liver disease
This study tests a new device called LiverScope® that scans your liver to detect fatty liver disease (MASLD). The scan uses special imaging technology and may help doctors diagnose liver disease more quickly and accurately.
La Jolla, CaliforniaAges 18 years+ - NCT07553663RecruitingPhase 1
Testing a new liver disease treatment for fatty liver
This study tests how your body processes a new medication called miricorilant, designed to help people with fatty liver disease (MASH). You'll have liver scans or recent biopsy results and metabolic conditions like diabetes or high blood pressure.
San Antonio, TexasAges 18–75 - NCT07632677Recruiting
Testing a liver inflammation score in diabetes and fatty liver
This study tests whether a new scoring method can help doctors identify liver inflammation in patients who have both type 2 diabetes and a fatty liver. The goal is to find an easier, safer way to assess liver health without invasive procedures.
Bengbu, AnhuiAges 18 years+ - NCT07646197Recruiting
Peanut Consumption and Fatty Liver Disease in Adults
This study tests whether eating peanuts regularly can help improve fatty liver disease (a condition where fat builds up in the liver). You'll be asked to eat peanuts as part of your diet while researchers track changes in your liver health.
Detroit, MichiganAges 30–70 - NCT07652151Recruiting
Fatty Liver Disease Study Using Wearable Tracking
This research studies fatty liver disease linked to metabolic problems like diabetes and obesity. You'll wear a fitness tracker and have liver imaging to help doctors understand the disease and find new treatments.
RomaAges 18 years+ - NCT07658755Recruiting
LiverSeek: Finding advanced liver scarring in MASLD
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
Madrid, MadridAges 50–75 - NCT06944353Enrolling by invitation
Fatty liver risk screening in the emergency department
This study looks at fatty liver findings on emergency department scans. If you have fatty liver and were sent home from the ED, the study may help connect you to follow-up care and avoid future liver problems.
Chicago, IllinoisAges 18 years+ - NCT07013916Recruiting
Fructose and liver health in fatty liver disease
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
LondonAges 45–65 - NCT06453915RecruitingEarly Phase 1
Brain PET scan for inflammation in fatty liver disease
This study uses a special PET scan to look for inflammation in the brain related to fatty liver disease. It may help researchers understand how liver health affects brain function.
Sacramento, CaliforniaAges 18 years+ - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT06354088RecruitingPhase 1
Study of alpelisib for insulin resistance
This study tests a single dose of a drug called alpelisib (a PI3K inhibitor) to see how it affects insulin and blood sugar in people who are either insulin sensitive or insulin resistant. The goal is to understand why some people become resistant to insulin, which may help find new treatments for diabetes and related conditions.
New York, New YorkAges 18–70 - NCT06449833RecruitingPhase 4
Henagliflozin for liver fat in diabetes and fatty liver
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Guangzhou, GuangdongAges 18–75 - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT07145151RecruitingPhase 2
Studying UBT251 for MASH liver disease
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
Beijing, Beijing MunicipalityAges 18–75 - NCT06937749RecruitingPhase 2
Study of IBI362 for liver scarring from MASH
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05945537RecruitingPhase 1
Testing INI-822 in healthy people and those with MASH
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
Camperdown, New South WalesAges 18–70 - NCT07463287Recruiting
Fatty liver and colorectal polyp risk study
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04014413Recruiting
Fecal transplant for gut and immune-related conditions
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hong Kong, ShatinAges Any age - NCT05984745RecruitingPhase 2
CoQ10 for fatty liver linked to metabolic issues
This study tests if CoQ10 (a natural supplement) can improve liver health in people with metabolic dysfunction-associated fatty liver disease (MAFLD). It may help if you have a fatty liver and related metabolic issues like high blood pressure or diabetes.
CairoAges 18–80
Hear when a new Metabolic Associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metabolic associated fatty liver disease?
- Yes. Clin2 currently lists 73 recruiting metabolic associated fatty liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metabolic associated fatty liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metabolic associated fatty liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metabolic Dysfunction-associated Fatty Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Associated Steatotic Liver Disease
- Metabolic Dysfunction-Associated Liver Disease
- Non-Alcoholic Fatty Liver Disease
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Fatty Liver
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.